We were delighted to meet with Messoud Ashina (University of Copenhagen, Copenhagen, Denmark) to discuss the long term safety and tolerability profile of atogepant, and its place as a preventative option for migraine.
The abstract entitled: ‘Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
1. What has the study taught us about the long term safety and tolerability profile of atogepant? (0:14)
2. What place is atogepant likely to play in the preventative treatment paradigm for migraine? (3:01)
Disclosures: Messoud Ashina has received personal fees from AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis and Teva; is the principal investigator for AbbVie/Allergan, Amgen, Eli Lilly and Lundbeck in ongoing clinical trials; has received Research grants form Lundbeck Foundation, Novo Nordisk Foundation, and Novartis; has no ownership interest and does not own stocks of any pharmaceutical company. Messoud Ashina is also an Associate Editor of Cephalalgia and associate editor of the Journal of Headache and Pain, and is the President of the International Headache Society.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Andrew Blumenfeld, AHS 2021: Combination use of OnabotulinumtoxinA and CGRP mAbs for Chronic Migraine
We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine. The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at […]
Richard Lipton, AHS 2021: COURAGE Study Results
touchNEUROLOGY met with Richard Lipton (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss the COURAGE study results investigating the Migraine Buddy Application. The abstract ‘Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence’ was presented at the American Headache Society […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!